Stora Enso Has Appointed Johanna Hagelberg As Executive Vice President Sourcing As Of 1 November 2014. This Is A New Role In Stora Enso's Group Leadership Team

Stora Enso has appointed Johanna Hagelberg as Executive Vice President Sourcing as of 1 November 2014. This is a new role in Stora Enso's Group Leadership Team .

Johanna Hagelberg joined Stora Enso in November 2013 as SVP Sourcing of the division Printing and Living. Prior to joining Stora Enso she held leading positions within sourcing at companies including Vattenfall, RSA Scandinavia and NCC.

"Johanna Hagelberg is a result-oriented professional and team-spirited manager. Her solid experience in procurement and operational excellence will strongly contribute to developing Stora Enso's partner relationships while building a competitive cost base," says Stora Enso's CEO Karl-Henrik Sundstrom.

Photo of Johanna Hagelberg is available at
http://bmt.storaenso.com/?cart=870-aamleciikm&l=EN

For further information, please contact:

Ulrika Lilja, EVP, Head of Global Communications, +46 72 221 92 28

www.storaenso.com
www.storaenso.com/investors

Stora Enso is the global rethinker of the paper, biomaterials, wood products and packaging industry. We always rethink the old and expand to the new to offer our customers innovative solutions based on renewable materials. Stora Enso employs some 29 000 people worldwide, and our sales in 2013 amounted to EUR 10.6 billion. Stora Enso shares are listed on NASDAQ OMX Helsinki (STEAV, STERV) and Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY) in the International OTCQX over-the-counter market.

STORA ENSO OYJ

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.